Browse by Section 100 Item List

Highly Specialised Drugs Program (Private Hospital)

For Pharmaceutical Benefits Scheme (PBS) Highly Specialised Drugs prescribed through private hospitals, claiming and approval of authority prescriptions is administered by Services Australia. Highly Specialised Drugs prescribed in private hospitals are Authority Required items. Application for authorisation can be made by either:

  • posting an Authority Prescription form and other application form(s), where applicable to Services Australia
  • using the form upload facility in Health Professional Online Services (HPOS)
  • using the Online PBS Authorities system (see www.servicesaustralia.gov.au/HPOS)
  • using the Services Australia free-call service for PBS Complex Drugs Programs enquiries (1800 700 270) or
  • using the appropriate Streamlined code.

Prescribers must quote the provider number of the hospital when applying. Maximum quantities and repeats for Highly Specialised Drugs are listed in the PBS Schedule. Authority approvals are required for prescriptions where the dose is above the determined maximum quantity and/or number of repeats.

Private hospital prescriptions for Highly Specialised Drugs can be dispensed by an approved private hospital dispensary or by a community pharmacy. A patient will be required to pay a contribution for each supply of a highly specialised drug at the same rate as the PBS.

The remuneration rates for Highly Specialised Drugs prescribed through private hospitals comprise the normal PBS ready-prepared dispensing fee plus a mark-up ascertained as follows:

  • 10% for drugs with an ex-manufacturer price of less than $40
  • $4 for drugs with an ex-manufacturer price of between $40 and $100
  • 4% for drugs with an ex-manufacturer price of between $100.01 and $1000
  • $40 for drugs with an ex-manufacturer price of greater than $1000.

Reciprocal Health Care Agreement – Where a patient is entitled to be treated as an eligible person as a visitor from a country with which Australia has entered into a Reciprocal Health Care Agreement, the supply will be limited to the original prescription only. Repeat prescriptions for these patients are not permitted.

  • Legend
  • MPMedical Practitioner
Prescriber code Item code Name, manner of administration and form & strength Max qty
packs
Max qty
units
No. of
repeats
MP 11237K OCRELIZUMABocrelizumab 300 mg/10 mL injection, 10 mL vial 2 2 0
MP 6229W OCTREOTIDEoctreotide 500 microgram/mL injection, 5 x 1 mL ampoules 18 90 11
MP 14177E OCTREOTIDEoctreotide 100 microgram/mL injection, 5 x 1 mL vials 18 90 11
MP 14213C OCTREOTIDEoctreotide 50 microgram/mL injection, 5 x 1 mL vials 18 90 11
MP 14201K OCTREOTIDEoctreotide 500 microgram/mL injection, 5 x 1 mL vials 18 90 11
MP 10566D OCTREOTIDEoctreotide 10 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack 2 2 5
MP 10549F OCTREOTIDEoctreotide 20 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack 2 2 5
MP 10558Q OCTREOTIDEoctreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack 2 2 5
MP 11894B OCTREOTIDEoctreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack 2 2 5
MP 6227R OCTREOTIDEoctreotide 50 microgram/mL injection, 5 x 1 mL ampoules 18 90 11
MP 6228T OCTREOTIDEoctreotide 100 microgram/mL injection, 5 x 1 mL ampoules 18 90 11
MP 10110D OMALIZUMABomalizumab 75 mg/0.5 mL injection, 0.5 mL syringe 1 1 7
MP 10956P OMALIZUMABomalizumab 75 mg/0.5 mL injection, 0.5 mL syringe 1 1 6
MP 11826K OMALIZUMABomalizumab 75 mg/0.5 mL injection, 0.5 mL syringe 1 1 0
MP 11840E OMALIZUMABomalizumab 75 mg/0.5 mL injection, 0.5 mL syringe 1 1 5
MP 11952C OMALIZUMABomalizumab 75 mg/0.5 mL injection, 0.5 mL syringe 1 1 5
MP 11958J OMALIZUMABomalizumab 75 mg/0.5 mL injection, 0.5 mL syringe 1 1 0
MP 10122R OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 1 1 7
MP 10968G OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 1 1 6
MP 11163M OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 2 2 5
MP 11175E OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 2 2 2
MP 11825J OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 1 1 0
MP 11864K OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 1 1 5
MP 11932B OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 1 1 0
MP 11953D OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 1 1 5